195 related articles for article (PubMed ID: 26671986)
1. The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.
Tanboon J; Williams EA; Louis DN
J Neuropathol Exp Neurol; 2016 Jan; 75(1):4-18. PubMed ID: 26671986
[TBL] [Abstract][Full Text] [Related]
2. Radiation-induced gliomas: a report of four cases and analysis of molecular biomarkers.
Nakao T; Sasagawa Y; Nobusawa S; Takabatake Y; Sabit H; Kinoshita M; Miyashita K; Hayashi Y; Yokoo H; Nakada M
Brain Tumor Pathol; 2017 Oct; 34(4):149-154. PubMed ID: 28795231
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic, prognostic and predictive relevance of molecular markers in gliomas.
Brandner S; von Deimling A
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):694-720. PubMed ID: 25944653
[TBL] [Abstract][Full Text] [Related]
4. The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features.
Cykowski MD; Allen RA; Kanaly AC; Fung KM; Marshall R; Perry A; Stolzenberg ED; Dunn ST
J Neurooncol; 2013 Dec; 115(3):477-86. PubMed ID: 24057326
[TBL] [Abstract][Full Text] [Related]
5. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
Karsy M; Guan J; Cohen AL; Jensen RL; Colman H
Curr Neurol Neurosci Rep; 2017 Feb; 17(2):19. PubMed ID: 28271343
[TBL] [Abstract][Full Text] [Related]
6. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
7. Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
Yamada S; Kipp BR; Voss JS; Giannini C; Raghunathan A
Am J Surg Pathol; 2016 Feb; 40(2):279-84. PubMed ID: 26414224
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of immunohistochemistry in the diagnosis of molecular genetic alterations in central nervous system gliomas: Next-generation sequencing of 212 mutations in 112 patients.
Daoud EV; Chkheidze R; Yell PC; Hatanpaa KJ; Raisanen JM; Cai C
Clin Neuropathol; 2022; 41(1):35-40. PubMed ID: 34672256
[TBL] [Abstract][Full Text] [Related]
9. Biomarker-driven diagnosis of diffuse gliomas.
Appin CL; Brat DJ
Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic markers in gliomas - an update.
Ma R; de Pennington N; Hofer M; Blesing C; Stacey R
Br J Neurosurg; 2013 Jun; 27(3):311-5. PubMed ID: 23278177
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of molecular biomarkers in gliomas.
Siegal T
J Clin Neurosci; 2015 Mar; 22(3):437-44. PubMed ID: 25533211
[TBL] [Abstract][Full Text] [Related]
12. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Polymerase Chain Reaction-Restriction Fragment Length Polymorphism, Immunohistochemistry, and DNA Sequencing for the Detection of IDH1 Mutations in Gliomas.
Malueka RG; Theresia E; Fitria F; Argo IW; Donurizki AD; Shaleh S; Innayah MR; Wicaksono AS; Dananjoyo K; Asmedi A; Hartanto RA; Dwianingsih EK
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3229-3234. PubMed ID: 33247679
[TBL] [Abstract][Full Text] [Related]
15. BRAF
Wang W; Wang M; Jiang H; Wang T; Da R
BMC Neurol; 2021 May; 21(1):195. PubMed ID: 33980169
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
Li J; Zhang H; Wang L; Yang C; Lai H; Zhang W; Chen X; Wang J
Mol Med Rep; 2015 Sep; 12(3):4376-4381. PubMed ID: 26130305
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P
Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690
[TBL] [Abstract][Full Text] [Related]
18. Comparison of immunohistochemistry and DNA sequencing for the detection of IDH1 mutations in gliomas.
Zou Y; Bai HX; Wang Z; Yang L
Neuro Oncol; 2015 Mar; 17(3):477-8. PubMed ID: 25556921
[No Abstract] [Full Text] [Related]
19. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas.
Takano S; Ishikawa E; Sakamoto N; Matsuda M; Akutsu H; Noguchi M; Kato Y; Yamamoto T; Matsumura A
Brain Tumor Pathol; 2016 Apr; 33(2):107-16. PubMed ID: 26968173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]